JRMS J Res Med Sci Journal of Research in Medical Sciences Journal of Research in Medical Sciences 1735-1995 1735-7136 Medknow Publications Pvt Ltd India JRMS-18-366 24124439 Commentary Changes in bone biological markers after treatment of Iranian diabetic patients with pioglitazone: No relation to polymorphism of PPAR-g (Pro12Ala) Mottaghi Peyman School of Medicine, Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Address for correspondence:Peyman Mottaghi, School of Medicine, Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran motaghi@med.mui.ac.ir April 2013 18 4 366 367 20 6 2012 21 8 2012 Copyright: © Journal of Research in Medical Sciences 2013

This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

<p>Sir</p> <p>The article "Changes in bone biological markers after treatment of Iranian diabetic patients with pioglitazone: No relation to polymorphism of PPAR-g (Pro12Ala) that published in recent issue encourage us to think about changes of bone mineral density with commonly used drugs to control hyperglycemia in type 2 diabetic patients.</p> <p>Thiazolidinediones including pioglitazone are agents that lower blood glucose by improving target cell response to insulin. <sup> <xref ref-type="bibr" rid="ref1">1</xref> </sup>Pioglitazone is a selective agonist for peroxisome proliferator-activated receptor-gamma (PPAR-g). Activation of nuclear PPAR-g receptors influences the production of a number of gene products involved in glucose metabolism. <sup> <xref ref-type="bibr" rid="ref2">2</xref> </sup>There are also evidences that these drugs could affect the process of bone remodeling. In animal studies, PPAR-g agonist treatment was followed by increased bone loss and impaired osteoblast function. <sup> <xref ref-type="bibr" rid="ref3">3</xref> </sup>Few human studies evaluated the effects of treatment with PPAR agonist on BMD and measures of bone turnover. Activation of PPAR-g pathway by an endogenous PPAR-g ligand inhibited the formation and activation of osteoclasts in human mesenchymal stem cells. <sup> <xref ref-type="bibr" rid="ref4">4</xref> </sup></p> <p>In a randomized study of healthy postmenopausal woman by Gray et al., to evaluating the effect of PPAR agonist treatment on BMD levels, treatment with rosiglitazone, a thiazolidinedione, was associated with decreased markers of bone formation and significantly decreased BMD after 14 weeks of regular use compare to placebo. <sup> <xref ref-type="bibr" rid="ref5">5</xref> </sup></p> <p>In the ADOPT study, including women from 30-60 years of age with type 2 diabetes, increased numbers of peripheral fractures were reported in patients treated with the thiazolidinedione rosiglitazone. <sup> <xref ref-type="bibr" rid="ref6">6</xref> </sup>A Previous study in humans on the effects of PPAR-g agonist treatment on fracture risk and BMD in patients with diabetes showed that adverse effects were seen in women only. <sup> <xref ref-type="bibr" rid="ref7">7</xref> </sup></p> <p>The human genome is highly polymorphic for common variation that confers susceptibility to common, complex diseases. These variants typically confer much weaker effects than variants associated with monogenic diseases, and must interact with other genes and environmental triggers to establish disease. This polymorphism may be responsible for variable cellular response to therapeutic or side effects of a drug. <sup> <xref ref-type="bibr" rid="ref8">8</xref> </sup></p> <p>It is known that pro12Ala polymorphism of PPAR-g reduces the transcriptional activity of PPAR and is involved in the pathogenesis of insulin resistance, and Osteoporosis. <sup> <xref ref-type="bibr" rid="ref9">9</xref> </sup>There is also some evidence that varied effect of thiazolidinediones in bone markers may be due to polymorphism of PPAR-g genes. Rhee et al., have reported the Pro12Ala polymorphism is significantly associated with lower serum OPG level as a key inhibitor of osteoclastogenesis, thus in favor of decrease bone density, <sup> <xref ref-type="bibr" rid="ref9">9</xref> </sup>but this sample of Iranian population have shown that the Pro12Ala polymorphism is not associated with low BMD at the lumbar spine and femoral neck. Currently, there are few data available on the skeletal actions of Pro12Ala in humans.</p> <p>According to available data, in both pre and postmenopausal diabetic women, long term follow-up studies are need to determine subgroup of patients, who are high risk for bone loss with thiazolidinediones use.</p> </sec> </body> <back> <ref-list> <ref id="ref1"> <label>1</label> <nlm-citation citation-type="journal"> <person-group person-group-type="author"> <name> <surname>Boden</surname> <given-names>G</given-names> </name> <name> <surname>Cheung</surname> <given-names>P</given-names> </name> <name> <surname>Mozzoli</surname> <given-names>M</given-names> </name> <name> <surname>Fried</surname> <given-names>SK</given-names> </name> </person-group> <article-title>Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes</article-title> <source>Metabolism</source> <year>2003</year> <volume>52</volume> <fpage>753</fpage> <lpage>9</lpage> </nlm-citation> </ref> <ref id="ref2"> <label>2</label> <nlm-citation citation-type="journal"> <person-group person-group-type="author"> <name> <surname>Nathan</surname> <given-names>DM</given-names> </name> <name> <surname>Buse</surname> <given-names>JB</given-names> </name> <name> <surname>Davidson</surname> <given-names>MB</given-names> </name> <name> <surname>Ferrannini</surname> <given-names>E</given-names> </name> <name> <surname>Holman</surname> <given-names>RR</given-names> </name> <name> <surname>Sherwin</surname> <given-names>R</given-names> </name> <etal /> </person-group> <article-title>Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy</article-title> <source>Diabetes Care</source> <year>2009</year> <volume>32</volume> <fpage>193</fpage> <lpage>203</lpage> </nlm-citation> </ref> <ref id="ref3"> <label>3</label> <nlm-citation citation-type="journal"> <person-group person-group-type="author"> <name> <surname>Rzonca</surname> <given-names>SO</given-names> </name> <name> <surname>Suva</surname> <given-names>LJ</given-names> </name> <name> <surname>Gaddy</surname> <given-names>D</given-names> </name> <name> <surname>Montague</surname> <given-names>DC</given-names> </name> <name> <surname>Lecka-Czernik</surname> <given-names>B</given-names> </name> </person-group> <article-title>Bone is a target for the antidiabetic compound rosiglitazone</article-title> <source>Endocrinology</source> <year>2004</year> <volume>145</volume> <fpage>401</fpage> <lpage>6</lpage> </nlm-citation> </ref> <ref id="ref4"> <label>4</label> <nlm-citation citation-type="journal"> <person-group person-group-type="author"> <name> <surname>Pittenger</surname> <given-names>MF</given-names> </name> <name> <surname>Thiede</surname> <given-names>MA</given-names> </name> <name> <surname>Marshak</surname> <given-names>DR</given-names> </name> </person-group> <article-title>Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation</article-title> <source>J Biol Chem</source> <year>2000</year> <volume>275</volume> <fpage>14388</fpage> <lpage>93</lpage> </nlm-citation> </ref> <ref id="ref5"> <label>5</label> <nlm-citation citation-type="journal"> <person-group person-group-type="author"> <name> <surname>Gray</surname> <given-names>A</given-names> </name> <name> <surname>Bolland</surname> <given-names>M</given-names> </name> <name> <surname>Gamble</surname> <given-names>G</given-names> </name> <name> <surname>Wattie</surname> <given-names>D</given-names> </name> <name> <surname>Horne</surname> <given-names>A</given-names> </name> <name> <surname>Davidson</surname> <given-names>J</given-names> </name> <etal /> </person-group> <article-title>The peroxisome proliferator-activated receptor-agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: A randomized, controlled trial</article-title> <source>J Clin Endocrinol Metab</source> <year>2007</year> <volume>92</volume> <fpage>1305</fpage> <lpage>10</lpage> </nlm-citation> </ref> <ref id="ref6"> <label>6</label> <nlm-citation citation-type="journal"> <person-group person-group-type="author"> <name> <surname>Kahn</surname> <given-names>SE</given-names> </name> <name> <surname>Haffner</surname> <given-names>SM</given-names> </name> <name> <surname>Heise</surname> <given-names>MA</given-names> </name> <name> <surname>Herman</surname> <given-names>WH</given-names> </name> <name> <surname>Holman</surname> <given-names>RR</given-names> </name> <name> <surname>Jones</surname> <given-names>NP</given-names> </name> <etal /> </person-group> <article-title>Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy</article-title> <source>N Engl J Med</source> <year>2006</year> <volume>355</volume> <fpage>2427</fpage> <lpage>43</lpage> </nlm-citation> </ref> <ref id="ref7"> <label>7</label> <nlm-citation citation-type="journal"> <person-group person-group-type="author"> <name> <surname>Schwartz</surname> <given-names>AV</given-names> </name> <name> <surname>Cummings</surname> <given-names>SR</given-names> </name> </person-group> <article-title>Does rosiglitazone adversely affect bone formation and bone mineral density in postmenopausal women?</article-title> <source>Pract Endocrinol Metab</source> <year>2007</year> <volume>3</volume> <fpage>622</fpage> <lpage>3</lpage> </nlm-citation> </ref> <ref id="ref8"> <label>8</label> <nlm-citation citation-type="journal"> <person-group person-group-type="author"> <name> <surname>Halushka</surname> <given-names>MK</given-names> </name> <name> <surname>Fan</surname> <given-names>JB</given-names> </name> <name> <surname>Bentley</surname> <given-names>K</given-names> </name> </person-group> <article-title>Patterns of single-nucleotide polymorphisms in candidate genes for blood presser homeostasis</article-title> <source>Nat Genet</source> <year>1999</year> <volume>22</volume> <fpage>239</fpage> </nlm-citation> </ref> <ref id="ref9"> <label>9</label> <nlm-citation citation-type="journal"> <person-group person-group-type="author"> <name> <surname>Rhee</surname> <given-names>EJ</given-names> </name> <name> <surname>Oh</surname> <given-names>KW</given-names> </name> <name> <surname>Yun</surname> <given-names>EJ</given-names> </name> <name> <surname>Jung</surname> <given-names>CH</given-names> </name> <name> <surname>Park</surname> <given-names>CY</given-names> </name> <name> <surname>Lee</surname> <given-names>WY</given-names> </name> <etal /> </person-group> <article-title>The association of Pro12Ala polymorphism of peroxisome proliferator-activated receptor-g gene with serum osteoprotegerin levels in healthy Korean women</article-title> <source>Exp Mol Med</source> <year>2007</year> <volume>39</volume> <fpage>696</fpage> <lpage>704</lpage> </nlm-citation> </ref> <ref id="ref10"> <label>10</label> <nlm-citation citation-type="journal"> <person-group person-group-type="author"></person-group> <article-title></article-title> <source></source> <year></year> <volume></volume> <fpage></fpage> </nlm-citation> </ref> </ref-list> </back> </article>